Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases

Luigi Portella, Rosamaria Vitale, Stefania De Luca, Crescenzo D'Alterio, Caterina Ieranò, Maria Napolitano, Anna Riccio, Maria Neve Polimeno, Luca Monfregola, Antonio Barbieri, Antonio Luciano, Andrea Ciarmiello, Claudio Arra, Giuseppe Castello, Pietro Amodeo, Stefania Scala

Research output: Contribution to journalArticle

Abstract

The CXCR4/CXCL12 axis plays a role in cancer metastases, stem cell mobilization and chemosensitization. Proof of concept for efficient CXCR4 inhibition has been demonstrated in stem cell mobilization prior to autologous transplantation in hematological malignancies. Nevertheless CXCR4 inhibitors suitable for prolonged use as required for anticancer therapy are not available. To develop new CXCR4 antagonists a rational, ligand-based approach was taken, distinct from the more commonly used development strategy. A three amino acid motif (Ar-Ar-X) in CXCL12, also found in the reverse orientation (X-Ar-Ar) in the vMIP-II inhibitory chemokine formed the core of nineteen cyclic peptides evaluated for inhibition of CXCR4-dependent migration, binding, P-ERK1/2-induction and calcium efflux. Peptides R, S and I were chosen for evaluation in in vivo models of lung metastases (B16-CXCR4 and KTM2 murine osteosarcoma cells) and growth of a renal cells xenograft. Peptides R, S, and T significantly reduced the association of the 12G5-CXCR4 antibody to the receptor and inhibited CXCL12-induced calcium efflux. The four peptides efficiently inhibited CXCL12-dependent migration at concentrations as low as 10 nM and delayed CXCL12-mediated wound healing in PES43 human melanoma cells. Intraperitoneal treatment with peptides R, I or S drastically reduced the number of B16-CXCR4-derived lung metastases in C57/BL mice. KTM2 osteosarcoma lung metastases were also reduced in Balb/C mice following CXCR4 inhibition. All three peptides significantly inhibited subcutaneous growth of SN12C-EGFP renal cancer cells. A novel class of CXCR4 inhibitory peptides was discovered. Three peptides, R, I and S inhibited lung metastases and primary tumor growth and will be evaluated as anticancer agents.

Original languageEnglish
Article numbere74548
JournalPLoS One
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 13 2013

Fingerprint

metastasis
Tumors
antagonists
peptides
Neoplasm Metastasis
neoplasms
Hematopoietic Stem Cell Mobilization
Growth
Stem cells
Lung
Peptides
lungs
Osteosarcoma
Neoplasms
Cells
osteosarcoma
Calcium
Cyclic Peptides
kidney cells
stem cells

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases. / Portella, Luigi; Vitale, Rosamaria; De Luca, Stefania; D'Alterio, Crescenzo; Ieranò, Caterina; Napolitano, Maria; Riccio, Anna; Polimeno, Maria Neve; Monfregola, Luca; Barbieri, Antonio; Luciano, Antonio; Ciarmiello, Andrea; Arra, Claudio; Castello, Giuseppe; Amodeo, Pietro; Scala, Stefania.

In: PLoS One, Vol. 8, No. 9, e74548, 13.09.2013.

Research output: Contribution to journalArticle

Portella, L, Vitale, R, De Luca, S, D'Alterio, C, Ieranò, C, Napolitano, M, Riccio, A, Polimeno, MN, Monfregola, L, Barbieri, A, Luciano, A, Ciarmiello, A, Arra, C, Castello, G, Amodeo, P & Scala, S 2013, 'Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases', PLoS One, vol. 8, no. 9, e74548. https://doi.org/10.1371/journal.pone.0074548
Portella, Luigi ; Vitale, Rosamaria ; De Luca, Stefania ; D'Alterio, Crescenzo ; Ieranò, Caterina ; Napolitano, Maria ; Riccio, Anna ; Polimeno, Maria Neve ; Monfregola, Luca ; Barbieri, Antonio ; Luciano, Antonio ; Ciarmiello, Andrea ; Arra, Claudio ; Castello, Giuseppe ; Amodeo, Pietro ; Scala, Stefania. / Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases. In: PLoS One. 2013 ; Vol. 8, No. 9.
@article{cc24ccf9c66046989599b784305ad236,
title = "Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases",
abstract = "The CXCR4/CXCL12 axis plays a role in cancer metastases, stem cell mobilization and chemosensitization. Proof of concept for efficient CXCR4 inhibition has been demonstrated in stem cell mobilization prior to autologous transplantation in hematological malignancies. Nevertheless CXCR4 inhibitors suitable for prolonged use as required for anticancer therapy are not available. To develop new CXCR4 antagonists a rational, ligand-based approach was taken, distinct from the more commonly used development strategy. A three amino acid motif (Ar-Ar-X) in CXCL12, also found in the reverse orientation (X-Ar-Ar) in the vMIP-II inhibitory chemokine formed the core of nineteen cyclic peptides evaluated for inhibition of CXCR4-dependent migration, binding, P-ERK1/2-induction and calcium efflux. Peptides R, S and I were chosen for evaluation in in vivo models of lung metastases (B16-CXCR4 and KTM2 murine osteosarcoma cells) and growth of a renal cells xenograft. Peptides R, S, and T significantly reduced the association of the 12G5-CXCR4 antibody to the receptor and inhibited CXCL12-induced calcium efflux. The four peptides efficiently inhibited CXCL12-dependent migration at concentrations as low as 10 nM and delayed CXCL12-mediated wound healing in PES43 human melanoma cells. Intraperitoneal treatment with peptides R, I or S drastically reduced the number of B16-CXCR4-derived lung metastases in C57/BL mice. KTM2 osteosarcoma lung metastases were also reduced in Balb/C mice following CXCR4 inhibition. All three peptides significantly inhibited subcutaneous growth of SN12C-EGFP renal cancer cells. A novel class of CXCR4 inhibitory peptides was discovered. Three peptides, R, I and S inhibited lung metastases and primary tumor growth and will be evaluated as anticancer agents.",
author = "Luigi Portella and Rosamaria Vitale and {De Luca}, Stefania and Crescenzo D'Alterio and Caterina Ieran{\`o} and Maria Napolitano and Anna Riccio and Polimeno, {Maria Neve} and Luca Monfregola and Antonio Barbieri and Antonio Luciano and Andrea Ciarmiello and Claudio Arra and Giuseppe Castello and Pietro Amodeo and Stefania Scala",
year = "2013",
month = "9",
day = "13",
doi = "10.1371/journal.pone.0074548",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases

AU - Portella, Luigi

AU - Vitale, Rosamaria

AU - De Luca, Stefania

AU - D'Alterio, Crescenzo

AU - Ieranò, Caterina

AU - Napolitano, Maria

AU - Riccio, Anna

AU - Polimeno, Maria Neve

AU - Monfregola, Luca

AU - Barbieri, Antonio

AU - Luciano, Antonio

AU - Ciarmiello, Andrea

AU - Arra, Claudio

AU - Castello, Giuseppe

AU - Amodeo, Pietro

AU - Scala, Stefania

PY - 2013/9/13

Y1 - 2013/9/13

N2 - The CXCR4/CXCL12 axis plays a role in cancer metastases, stem cell mobilization and chemosensitization. Proof of concept for efficient CXCR4 inhibition has been demonstrated in stem cell mobilization prior to autologous transplantation in hematological malignancies. Nevertheless CXCR4 inhibitors suitable for prolonged use as required for anticancer therapy are not available. To develop new CXCR4 antagonists a rational, ligand-based approach was taken, distinct from the more commonly used development strategy. A three amino acid motif (Ar-Ar-X) in CXCL12, also found in the reverse orientation (X-Ar-Ar) in the vMIP-II inhibitory chemokine formed the core of nineteen cyclic peptides evaluated for inhibition of CXCR4-dependent migration, binding, P-ERK1/2-induction and calcium efflux. Peptides R, S and I were chosen for evaluation in in vivo models of lung metastases (B16-CXCR4 and KTM2 murine osteosarcoma cells) and growth of a renal cells xenograft. Peptides R, S, and T significantly reduced the association of the 12G5-CXCR4 antibody to the receptor and inhibited CXCL12-induced calcium efflux. The four peptides efficiently inhibited CXCL12-dependent migration at concentrations as low as 10 nM and delayed CXCL12-mediated wound healing in PES43 human melanoma cells. Intraperitoneal treatment with peptides R, I or S drastically reduced the number of B16-CXCR4-derived lung metastases in C57/BL mice. KTM2 osteosarcoma lung metastases were also reduced in Balb/C mice following CXCR4 inhibition. All three peptides significantly inhibited subcutaneous growth of SN12C-EGFP renal cancer cells. A novel class of CXCR4 inhibitory peptides was discovered. Three peptides, R, I and S inhibited lung metastases and primary tumor growth and will be evaluated as anticancer agents.

AB - The CXCR4/CXCL12 axis plays a role in cancer metastases, stem cell mobilization and chemosensitization. Proof of concept for efficient CXCR4 inhibition has been demonstrated in stem cell mobilization prior to autologous transplantation in hematological malignancies. Nevertheless CXCR4 inhibitors suitable for prolonged use as required for anticancer therapy are not available. To develop new CXCR4 antagonists a rational, ligand-based approach was taken, distinct from the more commonly used development strategy. A three amino acid motif (Ar-Ar-X) in CXCL12, also found in the reverse orientation (X-Ar-Ar) in the vMIP-II inhibitory chemokine formed the core of nineteen cyclic peptides evaluated for inhibition of CXCR4-dependent migration, binding, P-ERK1/2-induction and calcium efflux. Peptides R, S and I were chosen for evaluation in in vivo models of lung metastases (B16-CXCR4 and KTM2 murine osteosarcoma cells) and growth of a renal cells xenograft. Peptides R, S, and T significantly reduced the association of the 12G5-CXCR4 antibody to the receptor and inhibited CXCL12-induced calcium efflux. The four peptides efficiently inhibited CXCL12-dependent migration at concentrations as low as 10 nM and delayed CXCL12-mediated wound healing in PES43 human melanoma cells. Intraperitoneal treatment with peptides R, I or S drastically reduced the number of B16-CXCR4-derived lung metastases in C57/BL mice. KTM2 osteosarcoma lung metastases were also reduced in Balb/C mice following CXCR4 inhibition. All three peptides significantly inhibited subcutaneous growth of SN12C-EGFP renal cancer cells. A novel class of CXCR4 inhibitory peptides was discovered. Three peptides, R, I and S inhibited lung metastases and primary tumor growth and will be evaluated as anticancer agents.

UR - http://www.scopus.com/inward/record.url?scp=84884132303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884132303&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0074548

DO - 10.1371/journal.pone.0074548

M3 - Article

C2 - 24058588

AN - SCOPUS:84884132303

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e74548

ER -